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Bacteriologic follow-up of schoolgirls with untreated covert bac-
teriuria.A. W. Asscher, E. R. Verrier-Jones, Kate Verrier Jones,
Ruth Mackenzie, and L. A. Williams. K.R. U.F. Institute of Re-
nal Disease, Welsh National School of Medicine, Royal In-
firmary, Cardiff Wales. Midstream urine specimens were ob-
tained at approximately 2-month intervals over a 4-year period
from 75 schoolgirls aged 5 to 12 years, with untreated covert bac-
teriuria. At the start, Escherichia coli strains were isolated from
all patients from catheter specimens of urine obtained during
voiding cystourography. In 16 (21%) of the 75 girls, a spontane-
ous cure of bacteriuria occurred mostly within the first year of
the detection of bacteriuria and mostly in girls in whom the uri-
nary tract was radiologically normal. In 22 (29%) of the girls,
bacteriuria persisted throughout follow-up. The organisms were
identical in serotype in 7, and changed serotype or even species
in 15. In 13 of the 22 girls with persistent bacteriuria, kidney
scarring, or vesico-ureteric refiux (VUR), or both, were present
initially. Progression of this kidney damage tended to occur more
so in the girls in whom VUR and persistent infection due to
changing pathogens were found. Thirty seven (50%) of the girls
had intermittent bacteriuria during follow-up. In 19 of these in
whom more than 15 isolates were available, a study of the sensi-
tivity of the organisms to the cidal effect of serum was under-
taken by Professor L. A. Hanson and Dr. S. OIling of the Depart-
ment of Immunology, University of GOteborg. In these 19 girls,
36 episodes of spontaneous clearance of bacteriuria followed by
reinfections took place. In 26 of these episodes, theE. coli strain
was highly sensitive to the cidal effect of human serum before the
urine became sterile. This suggests that spontaneous clearance
of urinary tract infection depends on changes in the surface
structure of E. coli induced by natural defensive mechanisms.
Complex dissolution: An assay for complement function and im-
mune-complex load. S. R. Bartolotti, B. Pussell, A. Dash, and
D. K. Peters. Renal Unit, Royal Postgraduate Medical School,
Hammersmith Hospital, London, England. Recent observations
on a new function of complement (C) have led us to assess it in
patients with diseases associated with circulating immune com-
plexes (dC). It has been reported that antigen-antibody precipi-
tates can be dissolved in vitro into small complexes under the
influence of C and that cobra venom factor-induced hypocomple-
mentaemia in rabbits with acute serum sickness results in de-
layed clearance of complexes from the glomerulus. This function
of C was examined in 170 patients using a simple radioimmuno-
assay: precipitates made of radioiodinated bovine serum albumin
and rabbit antibody were incubated in the presence of test serum
for 1 hour at 370 C. The fraction of complexes solubilized by
complement from the precipitate was expressed as a percentage
of the total radioactivity added. Abnormally low values were
found in patients with hypocomplementaemia, did (Clq binding
assay), and also in some patients in whom the complement pro-
file was normal and CIC undetectable. Sequential studies have
been performed in patients with SLE (9), vasculitis (3), and gb-
merulonephritis (5). A persistent abnormality of complex dis-
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solution was associated with continuing disease and returned to
normal with clinical remission. This is a simple assay that mea-
sures functional complement in one step and when combined
with calcium chelation also assays the alternative pathway. It is
able to discriminate between complement-solubilized and com-
plement-activating immune complexes as well as to detect anti-
complementary reactants. As it appears to be associated with
disease activity, it may be useful in patient management.
Release of vascular permeability factor from lymphocytes of pa-
tients with minimal change nephropathy. M. Boulton-Jones and
S. Simpson. Kidney Diseases Research Unit, Royal Infirmary,
Glasgow, Scotland. The pathogenesis of minimal change ne-
phropathy (MCN) is unknown, but some clinical and experimen-
tal observations suggest that the role of lymphocytes may be im-
portant. The effect of tuberculosis, which is a potent stimulator
of cell-mediated immunity, on the natural history of a patient
with MCN would be of interest and will be described. It has been
postulated that the lymphocytes of patients with MCN release a
factor (lymphokine) which increases vascular permeability, thus
causing proteinuria. We attempted to test this hypothesis by cul-
turing peripheral blood lymphocytes. Phytohaemagglutinin(PHA) was added to the stimulated (S) cultures, and saline to
control (R) cultures. The supernatant was harvested after 24 to
48 hours and assayed for vascular permeability by the Evans
Blue technique. The results were: Mean area of reconstituted
supernatant of control subjects (R1) was 32.8 mm2 (N = 10);
mean area of reconstituted supernatant of MCN patients (R2)
was 105.4 mm2 (N = 7); mean area of stimulated supernatant of
control subjects (S1) was 60.2 mm2 (N 10); mean area of stimu-
lated supernatant of MCN patients (S2) was 113.8 mm2(N 7).
The cells for these experiments were taken during relapse. Simi-
lar experiments failed to show any difference between the cells of
patients taken during remission and the control group. These re-
sults suggest that lymphocytes of patients with MCN produce
abnormal amounts of vascular permeability factor during relapse
even in the absence of an in vitro stimulant, presumably because
they have already been stimulated in vivo.
Serum ferritin concentration and oral iron therapy in patients on
regular hemodialysis. A. M. Cotterill, J. N. Flather, W. R. Cat-
tell, M. D. Barn ett, and L. R. I. Baker. Depart,'nent of Nephrolo-
gy, St. Bartholomew's Hospital, London, England. Serum fern-
tin concentration was measured in 61 hemodialysis patients re-
ceiving "low" (60 to 120 mg, N = 15), "intermediate" (121 to
240 mg, N = 28) or "high" (241 to 360 mg, N = 18) oral intakes
of elemental iron daily. Only 3 patients had ever received paren-
teral iron, and none had received parenteral iron within the pre-
vious 12 months. Mean serum ferritin concentration was 493 ,ag/
liter (range, 10 to 8600; normal range, 15 to 250 gIliter). Serum
ferritin was elevated in 44 patients, normal in 16, and reduced in
one. This last patient used a coil dialyzer whereas the remaining
60 used flat board dialyzers. Mean serum ferritin concentration
was significantly lower in the group receiving the "low" intake
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of iron than it was in each of the other two groups (P < 0.001 in
each instance). We conclude that it is unnecessary to exceed 120
mg of elemental iron daily to maintain iron balance in patients
treated by flat board hemodialysis provided that economy in
blood sampling is exercised. This dose is too large in some pa-
tients. We suggest an adequate maintenance dose for the major-
ity of patients to be 60 mg of elemental iron (one ferrous sulphate
tablet) daily.
Goodpasture's syndrome: Radioimmunoassay for measurement
of circulating anti-GBM antibody. C. M. Lockwood, N. Amos,
and D. K. Peters. Renal Unit, Royal Postgraduate Medical
School, Hammersmith Hospital, London, England. Using a col-
lagenase extract of glomerular basement membrane (GBM), we
have developed a robust and sensitive solid-phase radioimmuno-
assay to detect circulating antibodies to GBM in patients with
clinical and histologic features of anti-GBM nephritis. The tech-
nique relies on the binding of the collagenase extract to the wall
of a plastic tube and subsequent fixation of specific antibody from
diluted samples of patients' serum. By using a highly purified 125J
labeled goat antihuman IgG, we found the degree of binding to be
related to that produced by a standardized antibody eluted from
the kidney of a patient with anti-GBM nephritis. The binding is
less than 10% for patients with other forms of nephritis but may
be as high as 80% for patients with severe anti-GBM disease.
Using this technique we have so far documented 40 patients with
anti-GBM nephritis confirmed by renal biopsy. The application
of this assay in the management of patients presenting with se-
vere nephritis and the subsequent monitoring of therapy are dis-
cussed.
Urinary excretion of the Tamm-Horsfall glycoprotein in normal
subjects and in patients after renal transplant. R. D. Marshall and
A. Goodall. Department of Biochemistry, University of Strath-
clyde, Glasgow, and Department of Chemical Pathology, St.
Mary's Hospital Medical School, London, England. The Tamm-
Horsfall urinary glycoprotein is of considerable interest even
though we do not fully understand its functions. It is produced by
the luminal cells of the ascending limb of Henle's loop and of the
distal convoluted tubule. Production of the apoprotein on the
polysomes of the renal cells is followed by a complex series of
glycosylation reactions as the molecule travels through the cis-
ternae of the endoplasmic reticulum and Golgi's complex to
reach what appears to be the site of the predominant location,
associated with the plasma membrane. It is present on both the
tubular luminal surface and on the basal plasma membrane, in-
cluding its invaginations. The glycoprotein may be directly in-
volved in the development and maintenance of the hyperosmo-
larity of the renal medulla. There is release of Tamm-Horsfall
glycoprotein from the tubular cells into the tubular urine which
appears, at least in part, in voided urine. We have made mea-
surements of the glycoprotein in urine by a radioimmunoassay
procedure, and these assays are best done on urine samples
which have been dialyzed against water and freeze-dried. This is
because freeze-dried Tamm-Horsfall glycoprotein reacts more
effectively with antibody than does glycoprotein which has not
been subjected to freezing or freeze-drying, and this is true for
antibody raised against either freeze-dried antigen or nonfrozen
antigen. Thus, solutions of Tamm-Horsfall glycoprotein, when
radioimmunoassayed using a freeze-dried standard, appear to
contain only 6% of the true content. Slow freezing (10 to 30 mm
at 20° C) increases this to 40%, quick freezing C02/methanol,
shell freezing (30 to 60 s) to 62%, and freeze drying to the correct
value. The daily excretion of the glycoprotein by a normal sub-
ject does not change even if the volume of urine varies by up to a
factor of 2, and the total amount is apparently unrelated to the
volume of urine. The results obtained with renal transplant pa-
tients indicated that the excretion of Tamm-Horsfall glycopro-
tein does not necessarily begin with excretion of urine. The data
appear to fall into two groups. In the first, the urinary output of
the glycoprotein was found to increase as creatinine clearance
rose. None of these patients suffered a rejection episode over the
period of time that we were able to follow the urinary excretion
of the Tamm-Horsfall glycoprotein. In the other groups, all had
indications of rejection of the allograft within a relatively short
period of time after transplantation. The amount of Tamm-Hors-
fall glycoprotein excreted increased before the rejection episode
and fell during it.
Studies on mesangiocapillary glomerulonephritis in Finnish
Landrace sheep. C. P. Swainson and D. Thomson. The Medical
Renal Unit, Department of Medicine and the Pathology Depart-
ment, University of Edinburgh, Scotland. A spontaneous mesan-
giocapillary glomerulonephritis (MCGN) in young Finnish Land-
race lambs was described in 1974, and it was noted that this dis-
ease was almost identical to human MCGN. The human disease
is often associated with persistent hypocomplementaemia and
the presence of the C3 nephritic factor. Persistent low serum C3
levels from birth are seen in those lambs who will die from renal
failure 6 to 8 weeks later. Sibling lambs with normal C3 levels do
not develop the disease, and the frequency of the disease de-
pends on a particular ram mating with high-risk" ewes. During
the past two breeding seasons we have attempted to modify the
course of the disease using immunosuppressive drugs. From a
total of 62 live births, we identified 16 affected lambs with severe
hypocomplementemia. Blood was drawn within 12 hours of
birth, and C3 results were known the following day. Prednisone
(40 mg) and cyclophosphamide (5 mg/kg), orally, was started and
continued for 8 weeks or until death. We attempted to transmit
the disease from affected lambs to healthy siblings by twice-
weekly injections of 1 ml of serum. C3 was estimated weekly.
Postmortem examinations with renal histology were performed
on every lamb which died and renal biopsies on the survivors at
12 weeks. Mean plasma C3 level for affected lambs was 4.3
1.5% of that of controls and 61 22% and 52 27% for unaf-
fected siblings and normal lambs, respectively. Three lambs sur-
vived the experiments, and the mean survival of the others was
62 days, a little longer than that for previously untreated lambs,
but 5 of these died from infection and did not have advanced
renal disease at death. The surviving lambs showed only minor
glomerular disease. Serum C3 in treated affected animals rose to
12.1 13% of controls and rose into the normal range in all those
who survived for more than 6 weeks. No lambs given serum from
diseased lambs showed any change in complement levels, but
two had advanced MCGN when sacrificed. These results in-
dicate possible modification of the disease and of the hypo-
complementemia by immunosuppression, but the drugs used al-
so contributed to the high mortality.
Does the nephrotic syndrome increase the risk of cardiovascular
disease? V. J. Wass, R. J. Jarrett, andi. S. Cameron. Renal Unit
and Department of Community Medicine, Guy's Hospital, Lon-
don, England. A markedly increased incidence of ischemic heart
disease (IHD) has been reported in patients with nephrotic syn-
drome (NS), but this conclusion was based on two very small,
highly selected series. We therefore followed up all adults who
presented with NS in the SE. Thames Region between January
1972 and December 1975. 1)iabetics and patients aged < 15 years
at presentation were excluded. Every patient was traced. If de-
ceased, the cause of death was established from postmortem
data and hospital notes. If alive, they were asked to (a) com-
plete a standard questionnaire to assess symptoms of angina and
intermittent claudication, (b) have a 12-lead resting elec-
trocardiogram (ECG) and, (c) attend fasting for measurement of
plasma lipids and glucose tolerance. One hundred fifty-nine adult
nephrotics (mean age [so]49.0 17.1 years) were followed for
a mean of 4.9 years (total group follow-up, 784 years). Forty nine
(3 1%) were dead or had nonfunctioning kidneys (mean age, 53.0
17.4 years); of these, 8 were alive on dialysis or transplant
programs; 21 had died in chronic renal failure, and 20 from other
causes, which included 4 deaths from IHD. This incidence of
death from IHD does not differ significantly from that in the gen-
eral population. One hundred eight patients (68%) were alive
(mean age, 47.4 16.7 years). Fifty nine had had continuous and
37 intermittent proteinuria, and 12 one episode of proteinuria on-
ly (< 6 months) over the follow-up period. Two cases remain
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untraced. To date, 104 questionnaires and 73 ECGs have been
completed. For each sex and age decade, the incidence of angi-
na, intermittent claudication, or ischemic ECG abnormality are
not significantly different from a control population. Known risk
factors for IHD were also assessed at follow-up. Hypertension
was present in 33% of the nephrotic patients. Total plasma cho-
lesterol was elevated in 34% and total plasma triglyceride in 19%.
High-density lipoprotein (HDL) cholesterol levels were, how-
ever, normal in all patients studied to date. Glucose tolerance
was not impaired. Thus after a mean follow-up of 4.9 years, an
increased incidence of cardiovascular disease could not be de-
tected in this predominantly middle-aged population of patients
presenting with nephrotic syndrome. Hypertension was signifi-
cantly increased, but HDL cholesterol levels were normal. Rou-
tine treatment of hyperlipidemia in unselected adult nephrotics
is not indicated.
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New method of water treatment for hemodiatysis. A. Abadie, P.
Bee, J. M. Pub, J. L. Lacombe, F. Maiha, D. Marty, and M.
Muslin. Clinique Saint-Exupéry, Toulouse, France. Since July
1977, French pharmacopoeia has recommended that water used
in hemodialysis contain limited quantities of anions and cations.
With the exception of total demineralization and distillation, no
current procedure meets these specifications. Particularly con-
spicuous in this regard is the softening technique, which is ac-
ceptable with regard to cations but not with regard to anions.
However, this shortcoming can be eliminated by combining the
softening procedure with an anionic permutation reaction. All
anions, particularly those most prohibited, NO3-, NO2-, F-, are
eliminated from the water and replaced by equivalent quantities
of CH3COO ions. This reaction also occurs using an ion ex-
changer according to the equation:
RCH3COO- + F- -* RF- + CHCOO
Resin
Infiowing anionic salts are totally transformed into CH3COO-
ions. In addition, this anion is used for the dialysate at approxi-
mately 35 mEq/liter and its desorption in front of all water anions
is very easy. Regarding the technical aspects: (1) the process is
combined in the same column with softening resin, (2) the regen-
eration of the two functions is achieved simultaneously by means
of a sodium acetate brine. The obtained results, using a proto-
type, are presented along with a perspective concerning appli-
cation in hemodialysis and peritoneal dialysis.
HDL cholesterol as cardiovascular risk factor in uremia. F.
Delavelle, J. C. Tromberl, and G. Canarelli. Service de
Nephrologie, Centre Renal Ermilage, Evian les Bains, France.
HDL cholesterol levels were studied concurrently with 'stan-
dard" blood lipid analysis in 105 subjects subdivided into three
groups: (I) healthy subjects (34 cases), (2) patients with severe
renal failure (serum creatinine, 60 to 100 mg/liter) (18 cases), (3)
chronic hemodialyzed patients (53 cases). Hypertriglyceridemia
was a predominant feature in group 2 (22% of cases with a mean
range of 2.60 0.59 g/liter) and group 3 (21% of patients; mean
range, 2.40 0.75 g/liter). Its incidence was reduced in African
hemodialyzed patients but was not influenced by sex, age, or
carbohydrate and caloric intake (although triglycendemia was in
the normal range positively correlated with carbohydrate intake:
r = + 0.56, P < 0.01). Total blood cholesterol was normal in the
three groups, but HDL cholesterol and the cs//3 cholesterol ratio
was significantly reduced (P < 0.00 1) in groups 2 (respectively,
0.32 0.11 and 0.21 0.08 g/liter) and 3 (0.39 0.11 and 0.27
0.12 glliter) as compared to group 1(0.54 0.15 and 0.42 0.21
g/liter). This drop in cholesterol was more pronounced in males
but was not related to age, ethnic origin, or the presence of dys-
lipidemia according to Frederickson's classification (HDL cho-
lesterol, 0.42 0.14 g/liter in type IV dyslipidemia and 0.40 g/
liter in hemodialyzed patients without dyslipidemia). However,
we found a positive correlation (r = 0.80, P < 0.05) between
nerve conduction velocity and HDL cholesterol, and cholesterol
was significantly decreased (P < 0.01) in group 2(0.32 0.11 g/
liter) when compared to the dialyzed patients in group 3 (0.39
0.11 g/liter). We suggest that better adequacy of dialysis may de-
crease cardiovascular risk in uremic patients by increasing HDL
cholesterol serum level.
Continuous peritoneal dialysis in the treatment of end-stage re-
nal failure. M. Dratwa, P. Vereerstraeten, and C. Toussaint.
Départenent de NCphrologie, Cliniques Universitaires de Brux-
cues, Höpital Brugmann and Hôpital Erasine, Bruxelles, Bel-
gium. Three patients with end-stage renal failure with residual
creatinine clearance under 2 mI/mm were treated by continuous
peritoneal dialysis (CPD), as advocated by Popovich, with four
2-liter exchanges per day, 5 days per week. As each patient had
been previously treated by hemodialysis (HD) and/or inter-
mittent peritoneal dialysis (IPD), it was possible to compare the
efficiency of CPD to that of conventional methods. The table
shows the serum concentrations (mean + SEM) of urea, creati-
nine, uric acid, phosphorous, and proteins observed in the three
patients in the course of the different modes of therapy used.
Phosphorus
mg/dI
.Patient Urea
tng/dl
Creatinine
mg/dl
Uric acid
mg/dl
Proteins
g
Patient I (female, 73 yr)
IPD 208 days
CPD 22days
201 6.5
109 9.0
7.7 2,2
6.8 3.1
11.9 2.6
8.3 3.2
5.2 2.8
3.0 1.4
6.7 0.9
5.4 1.1
Patient 2 (female, 57 yr)
IPD ll6days
CPD 28 days
179 9.0
56 5.0
11.0 0.4
6.1 0.3
10.7 0.6
5.5 0.3
4.1 0.3
2.0 0.2
6.1 0.3
4.9 0.1
Patient 3 (male, 59 yr)
HD 335 days
IPD 82 days
CPD 28 days
157 9.7
181 15.8
63 7.6
14.3 8.1
16.0 7.4
8.1 3.6
11.2 6.6
14.0 4.4
6.7 2.3
5.7 4.9
5.6 3.2
3.2 1.7
6.5 0.9
5.7 2.0
4.4 1.8
